Brief: Celularity Receives Orphan Drug Designation From U.S. FDA For Its NK Cell Therapy CYNK-101
15/02/2022 21:13
Feb 15 (Reuters) - Celularity Inc CELU.O :
* CELULARITY RECEIVES ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR ITS NK CELL
THERAPY CYNK-101 IN DEVELOPMENT FOR THE FIRST-LINE TREATMENT OF ADVANCED
HER2/NEU POSITIVE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCERS
Source text for Eikon: ID:nGNX9gYhVX
Further company coverage: CELU.O
Recent news on Celularity
See all newsU.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Celularity hits over 4-month high on deal to manufacture MuseCell's cell therapy platform
Celularity rises on deal to manufacture MuseCell's cell therapy platform
Brief: Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform